We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Throughput Tracking Ribosome Technique May Revolutionize Drug Discovery

By Biotechdaily staff writers
Posted on 04 Apr 2007
The ribosome is like a factory for protein production in the cell, and as such, has long been a key target for drug discovery. More...
Now, a technologic development is set to revolutionize research in this field.

For the first time, scientists from Weill Cornell University Medical College (New York, NY, USA) have developed a way to observe at the molecular level, real-time movies of significant structural processes within the ribosome underpinning the synthesis of protein. They were able to do it in a manner that should someday allow for screening of novel drugs that inhibit the ribosome or for the improvement of existing antibiotics that are sometimes toxic.

"This is really a proof-of-principle of what we hoped we could achieve--that we can make these types of measurements in a very robust and high-throughput manner,” reported study senior author Dr. Scott Blanchard, assistant professor of physiology and biophysics at Weill Cornell Medical College. His team published their findings in the March 23, 2007, issue of the journal Molecular Cell.

The ribosome is comprised of approximately 60 different molecules. These molecules work together in complicated ways, using instructions found in RNA to produce the proteins that cells need to live and grow. In the field of drug development, it is hard to overestimate the importance of the ribosome--for example, more than 50% of current antibiotics target this major cellular machine.

"Genetic instructions are presented to the ribosome in the form of messenger RNA,” explained Dr. Blanchard. "The process of translating those mRNA instructions into proteins involves the selection by the ribosome of RNA molecules called transfer RNA [tRNA].”

This selection process is the determining factor linking gene sequences with their end-product proteins. However, for years, much of what scientists know about ribosomal activity--and how drugs might affect it--has been conjecture, since it has been virtually impossible to view molecular activity within this tiny structure firsthand.

However, Dr. Blanchard's research has yielded a breakthrough: an advanced technology in microscopy called single-molecule fluorescence resonance energy transfer (smFRET) that uses long-established technologies in a whole new way.

"Using this technique, we're able to collect photons of light coming from many single molecules simultaneously,” Dr. Blanchard explained. "This information reports on a biomolecule's location, its interaction with other molecules, and tiny motions within the molecule itself. Before this technology, investigations of molecular processes were like trying to figure out how cars worked by watching traffic on the freeway from a satellite high up in space. Now, it's as if we're able to able to inspect the individual cars directly. In fact, both are important but having this new perspective should go a long way towards improving our understanding of how these machines operate.”

Observing one molecule at a time is fine, but effective drug discovery requires the rapid analysis of hundreds or even thousands of compounds in a high-throughput manner. In their latest research, Dr. Blanchard's team used smFRET to track sub-nanometer movements in tRNA positions deep within the ribosome (that is a distance change of approximately one hundred millionths of an inch).

"We observed three discrete configurations of tRNA within the ribosome that interconvert on the 100 millisecond timescale, including an intermediate hybrid configuration that no one had ever had evidence of before,” the researcher stated. The ability of scientists to make nearly real time measurements of how the ribosome's structure changes during function may be the study's biggest achievement. "Not only can you make exquisitely sensitive measurements on ribosome structure over time, you can also detect how the system changes in response to ligands, including antibiotics,” Dr. Blanchard said. "Those measurements should be able to be performed in a high-throughput manner,” he noted.

"Our next step is to watch how specific drugs affect the dynamic processes within the ribosome,” added Dr. Blanchard. "We hypothesize that drugs activities that block normal ribosomal functions can be detected by measuring how they change the cadence of structural events in the molecule. As my graduate advisor coined it, it's like a molecular EKG [electrocardiogram]. This new, close-up look at how molecular machines work, and how they are affected by therapeutic agents should open the door to better opportunities in drug discovery.”


Related Links:
Weill Cornell University Medical College

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Steam Sterilizer
Hi Vac II Line
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.